(BFW) *TEVA IS NOT FOR SALE: INTERIM CEO

+------------------------------------------------------------------------------+

BN 12/10 14:11 *TEVA INTERIM CEO SAYS CO. WILL EVALUATE BUYBACK OPPORTUNITIES BN 12/10 14:11 *TEVA INTERIM CEO SAYS CO. SEES DIVIDEND RISING IN 2014 BN 12/10 14:08 *TEVA IS NOT FOR SALE: INTERIM CEO BN 12/10 14:02 *TEVA WOULD NOT IGNORE ANY DEAL OPPORTUNITY: INTERIM CEO BN 12/10 14:02 *TEVA SEEKS ACQUISITIONS TO EXPAND IN EMERGING MKTS BN 12/10 14:01 *TEVA INTERIM CEO SAYS CO. HAS ABILITY TO EXECUTE DEALS BN 12/10 13:57 *TEVA SEES ABT 25% COPAXONE PTS SWITCHING IF GENERIC IN JUNE '14 BN 12/10 13:52 *TEVA SEES ORAL MS DRUGS ABOVE 100K PATS BY END-2014 BN 12/10 13:49 *TEVA INTERIM CEO SEES COPAXONE UNCERTAINTY THROUGH 2015 BN 12/10 13:48 *TEVA INTERIM CEO SAYS WILL KEEP SEEKING COST CUTS THROUGH 2014 BN 12/10 13:44 *TEVA SEES LOW-SINGLE-DIGIT PRICE EROSION IN EUROPE MKT IN '14 BN 12/10 13:34 *TEVA SEES 2014 A `VALLEY' FOR NEW GENERIC DRUGS BN 12/10 13:27 *TEVA SEES 1Q AND 4Q 2014 BETTER THAN 2Q AND 3Q BN 12/10 13:17 *TEVA INTERIM CEO SAYS FINDING PERMANENT CEO IS `HIGH PRIORITY' BN 12/10 13:12 *TEVA EXECUTIVES SPOKE IN CONFERENCE CALL BN 12/10 13:11 *TEVA INTERIM CEO SEES 70% OF COST SAVINGS REALIZED BY END-2015

+------------------------------------------------------------------------------+

*TEVA IS NOT FOR SALE: INTERIM CEO 2013-12-10 14:09:14.245 GMT

--LIBBY SALLABERRY

-0- Dec/10/2013 14:09 GMT

(CNBC +) Get ready, here it comes: A December taper

It increasingly appears that tapering is coming at the Fed's meeting next week.

While forecasting the central bank's moves has been an uncertain proposition for most of the past several months—with the conventional wisdom having it wrong in June and September—several of the Fed's own financial tests for reducing its asset purchases look to have been met as it heads into the Dec. 17 meeting. Those include confidence in the outlook, an easing of fiscal drag and uncertainty, and what the Fed sees as more appropriate interest rates.

To be sure, the Fed could decide to wait another month for even greater clarity, and practically, many Fed officials see little difference in a taper program that begins in December versus January.

But it looks as if the three tests for tapering have nearly been met.

(Read more: Global economy might be comeback story of 2014)
Confidence in the outlook: As of Friday's jobs reports, three-month average job growth is 193,000, up by 44,000 compared with what the Fed knew about payroll growth in September, when it surprised markets by failing to taper. Job growth in three of the past four months has been above 200,000. At 7 percent, the unemployment rate is two-tenths lower than in September.

Add to that an easing of tension in Europe and growing household wealth with stock and real estate values higher, and the Fed has ample reason to feel better about the economy and the outlook than it did in late summer.
End of fiscal uncertainty: Most Fed officials talk with increasing certainty about a pickup in growth next year. Part of that confidence is simple math. They see the effects of fiscal drag from government cutbacks easing next year and a waning impact from the January rise in tax rates. The Fed said explicitly in September that it was concerned about the negative effects of a looming government shutdown. Its political forecasting turned out to be on the mark (better, in fact, than its economic forecasting).

It now appears that congressional Democrats and Republicans are on the verge of a deal to put off another debilitating deficit debates for at least two years. That should give the Fed more confidence in the outlook even though fourth-quarter growth is expected to be in the 1 percent range.

(Read more: 'It is time to taper' says Fed's Fisher)
Interest rates: This is the one area that could yet sway the debate the other way, but on balance, it favors a tapering. The 10-year benchmark Treasury bond, at around 2.84, is pretty much where it was in September when the Fed said in its statement "tightening of financial conditions observed in recent months, if sustained, could slow the pace of improvement in the economy and labor market."

But there are some key differences. First, short rates have been far more well-behaved, indicating to Fed officials that markets embrace their notion that "tapering is not tightening,"—that is, reducing asset purchases should not bring forward the date when the market expects the Fed to hike interest rates. Indeed, the Fed Funds Futures contract for June 2015 traded as high as 92 basis points in September and 66 basis points the day before the September meeting. That same contract now trades at around 27 basis points.

Significantly, it did not move at all after Friday's surprisingly strong jobs report. The Fed takes this as the markets' belief in its pledge to keep rates "lower for longer" than would seem appropriate under normal economic conditions.

Second, the unemployment rate is lower, and third-quarter gross domestic product was revised up to 3.6 percent last week from the initial report of 2.8 percent. Fed officials are unlikely to fight hard against them if they perceive that they result from a better growth outlook.

Jeff Rosenberg, co-head of fixed income at BlackRock, said that the Fed's concern with higher long rates could keep a ld on their levels, with investors unwilling to bid up rates too high for fear that the Fed would act to tamp themmments Monday. down.

(Read more: Is Fed causing deflation? Some think so)
What's also clear is that several centrists on the rate-setting Federal Open Market Committee appear ready to discuss a taper, and some even have publicly called for a reduction. Notably, St. Louis Fed President Jim Bullard said Monday, "A small taper might recognize labor market improvement while still providing the committee the opportunity to carefully monitor inflation during the first half of 2014."

Atlanta Fed President Dennis Lockhart said last week that tapering should be discussed, and Jeff Lacker, president of the Richmond Fed, weighed in with similar co

(BFW) Orco Threatened by Bankruptcy Without More Capital, Vitek Says

+------------------------------------------------------------------------------+

BN 12/10 13:43 Orco Threatened by Bankruptcy Without More Capital, Vitek Says

+------------------------------------------------------------------------------+

Orco Threatened by Bankruptcy Without More Capital, Vitek Says 2013-12-10 13:47:44.430 GMT

By Jurjen van de Pol Dec. 10 (Bloomberg) -- Orco Property Group will go bankrupt unless it’s allowed to boost its capital, Czech billionaire Radovan Vitek, the company’s largest shareholder, tells Bloomberg’s Lenka Ponikelska. * Story: NSN MXLFH16KLVS8<GO>

For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO> --Editor: James Ludden

To contact the reporter on this story: Jurjen van de Pol in Frankfurt at +49-69-9204-1104 or jvandepol@bloomberg.net

To contact the editor responsible for this story: James Ludden at +44-20-7673-2645 or jludden@bloomberg.net

>>> Ukrainian Overnight Rates Spike To 20% As Bank Liquidity Fears Soar

As opposition party offices are raided and streets continue to fill with protesters, the "precarious" funding sitaution in the nation is beginning to flash red as interbank lending rates spike to 20%. Banks, clearly concerned about their own and each other's liquidity in the face of potential deposit runs (and the accompanying counterparty risk) and huge demand for liquidity. The hryvnia is falling and bond yields are rising but it is the spike in KievPrime overnight rates that is most concerning - and policy-makers have little room to help.

>>> US Gapping Down

Gapping down

In reaction to disappointing earnings/guidance: PBY -11.3%, ALOG -9.9%, CASY -1.2%, TPLM -1.1% (light volume), TEVA -0.6%, KMG -0.5%, TXN -0.3%.

Select shipping related names showing weakness: GNK -16.2%, EGLE -12.7%, VLCCF -2.4%, .

Other news: IEP -6.3% (announces sale of 2 mln depositary unit), GASS -5.8% (announces public offering of 10 mln shares of common stock), TA -5.4% (TravelCenters of America LLC Announces Public Offering of 5,000,000 Common Shares), ARCC -3.8% (plans to make a public offering of 14,300,000 shares of its common stock), DAR -3.7% (announced that it intends to offer 40,000,000 shares of its common stock in an underwritten public offering), BCRX -3.7% / NVAX -0.8% (still checking), PF -3.5% (announces secondary offering of 17 mln shares of common stock), SEAS -2.8% (filed amended S-1 prior to close), ALU -2.2% (still checking), NXPI -2% ( Selling shareholders commence 25 mln share secondary offering of common stock), TAM -1.5% (proposed secondary offering of 10 mln shares of common stock), FNSR -1.3% (announces proposed $200 mln convertible Senior notes offering due 2023), RL -0.7% (still checking), HTS -0.2% (declares Q4 dividend of $0.50 per share; previous quarter's dividend was $0.55 per share), NOK -0.7% (Nokia may pay $487 mln to India to transfer factory to Microsoft (MSFT), according to reports), .

Analyst comments: TEN -0.7% (Tenneco downgraded to Outperform at RBC Capital Mkts; tgt $66)

>>> US Gapping Up

Gapping up

In reaction to strong earnings/guidance: CMTL +6.4%, DIOD +4.7%, ABM +4.5%, TOL +3.6%, LL +1.2%, BURL +0.5%, (light volume), HITK +0.2%, (light volume).

M&A related: VTNC +6.1% (Vitran to be acquired by Manitoulin Transport for $6.00 per share), TI +4.5% (Telecom Italia not considering breakup of TIM Participacoes, according to reports ), TBOW (Trunkbow enters into merger agreement for 'going private' transaction for $1.46/share).

Select Brazil related names showing strength: CIG +9.8%, GFA +4.7%, PBR +1.3%.

Select metals/mining stocks trading higher: AG +2%, GDX +1.8%, NEM +1.7%, AU +1.7%, GFI +1.7%, GG +1.6%, SLV +1.5%, AUY +1.3%, ABX +1.2%, GOLD +0.2%.

Other news: GERN +16.8% (Geron seeing some volatility in after hours trading; co presented data on imetelstat at ASH and is scheduled to host an analyst and investor meeting; upgraded to Buy at Needham), NAVB +14.8% (FDA grants fast track designation to Navidea Biopharmaceuticals' Lymphoseek for sentinel lymph node detection in patients with head and neck cancer ), SYN +12% (Synthetic Biologics and Intrexon (XON) initiate Development of Novel Biologics for a Subset of Patients Suffering from Irritable Bowel Syndrome ), RMBS +7.9%/ MU +0.3% (Rambus and Micron sign license agreement), DRWI +7.8% (continued strength), NURO +6.7% (to partner with Omron Medical Devices for Distribution of NC-stat DPNCheck in China), CTIC +4.4% (presents interim results from Phase 2 Tosedostat Trial in older patients with acute myeloid leukemia or myelodysplastic syndrome), HL +4.2% (still checking), PLUG +4.2% (continued strength), LULU +2.9% (appoints Laurent Potdevin as CEO), ARWR +2.7% (presents Phase 1 Data on ARC-520 at HepDART 2013 -- New data including pharmacokinetics (PK) and adverse event (AE) attribution presented today in a poster and in an oral presentation tomorrow, support the previous findings that ARC-520 appears to be generally safe and well-tolerated at all six dose levels studied), ACI +2.6% (has begun operating its longwall mining system), IRM +2.5% (discloses it entered into a REIT Status Protection Rights Agreement), STM +2.3% (still checking), EVTC +2% (announces commencement of public offering of 15,287,473 shares of its common stock by selling stockholders and concurrent repurchase of its common stock), SODA +1.3% (following late spike), MED +1% (announces it has completed repurchase 786k shares of common stock under 1.125 mln share authorization at average price of $25.46), HON +0.7% (announces Major Investments to Increase HFO-1234yf Production in the United States), PXD +0.5% (still checking), BA +0.5% (WSJ discusses Boeing's (BA) tactics to lower its taxes), GM +0.4% (Treasury sold its remaining stake), TWC +0.4% (Time Warner Cable and Charter (CHTR) execs are in no rush for deals, according to reports), YHOO +0.3% (to give more details on revenue composition, according to reports), NAT +0.3% (issues latter to shareholders; says 'Bright spots on the horizon are the strong tendencies we see in global ton-mile demand '), ENDP +0.2% (receives FDA 510(k) clearance of the RetroArc Retropubic Sling System for treatment of female stress urinary incontinence), KO +0.2% (plans to introduce low calorie Coke, according to reports )

Analyst comments: HAWK +9.8% (upgraded to Buy from Neutral at Citigroup), RLYP +5.6% (initiated with an Overweight at Morgan Stanley, initiated with a Outperform at Wedbush), ARIA +4.9% (upgraded to Buy from Hold at Stifel), NVMI +1.4% (initiated with a Buy at Canaccord), DDD +1.3% (initiated with a Buy at Deutsche Bank), OSIS +1.1% (Sell-off is overdone; risk of debarment is low -- The Benchmark Company ), SSYS +1% (initiated with a Buy at Deutsche Bank), JCI +1% (upgraded to Top Pick at RBC Capital Mkts; tgt $61), RDS.A +0.6% (upgraded to Neutral from Underweight at JP Morgan), PKI +0.5% (upgraded to Outperform from Neutral at Macquarie ), URI +0.4% (upgraded to Top Pick at RBC Capital Mkts), HAR +0.1% (upgraded to Outperform from Market Perform at Wells Fargo).

>>> Celesio is trading below offer price on Elliott comments

Elliott Rejects McKesson Offer for Celesio, Suggests Breakup

Paul Singer’s Elliott Management to reject McKesson’s tender offer for outstanding shrs, convertible bonds of Celesio, Elliott says in statement.
  • Says bid substantially undervalues Celesio, doesn’t provide a “fair deal”
  • Says if McKesson paid a fairer price, could still benefit from accretive deal; estimates each incremental euro offered per Celesio shr would only reduce accretion amount by 3c
  • Suggests alternative to maximize investor value would be to sell Celesio wholesale business to one buyer and pharmacy business to another
  • NOTE: Dec. 5, McKesson offered EU23/shr for Celesio or EU3.9b, including debt EU6.1b
    • Bid terms include minimum acceptance threshold of 75% on a fully diluted basis
    • McKesson currently holds ~50.51% of Celesio voting rights (Franz Haniel stake)
    • Elliott says it holds over 25% of voting rights

(BFW) Elliott Capital Says McKesson’s Celesio Bid Too Low, Dj Says

+------------------------------------------------------------------------------+

BFW 12/10 12:43 *ELLIOTT CAPITAL SAYS MCKESSON’S CELESIO BID TOO LOW, DJ SAYS

+------------------------------------------------------------------------------+

Elliott Capital Says McKesson’s Celesio Bid Too Low, Dj Says 2013-12-10 12:48:26.542 GMT

By Joshua Fineman Dec. 10 (Bloomberg) -- Elliott Capital not satisfied with McKesson’s takeover offer for Celesio, DJ said, citing people familiar. * Elliott considers breakup of Celesio to be a better deal * NOTE: Oct. 24: McKesson offered to buy Celesio for EU23-shr {NSN MV5SJO6JIJUO <go>} * NOTE: Nov. 26, Celesio said Elliott held 25.16% voting rights on Nov. 19; {NSN MWVFK36JTSEW <go>}

Link to Company News:{CLS1 GR <Equity> CN <GO>} Link to Company News:{MCK US <Equity> CN <GO>}

For Related News and Information: First Word scrolling panel: {FIRST<GO>} First Word newswire: {NH BFW<GO>}

To contact the editor responsible for this story: Joshua Fineman at +1-212-617-8953 or jfineman@bloomberg.net